SrikarRMalireddyMD

PubMed

• 23 citations
  Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin
  Sara K. Quinney, Srikar R. Malireddy, Raj Vuppalanchi, Mitchell A. Hamman, Naga Chalasani, J. Christopher Gorski, Stephen D. Hall> ;European Journal of Clinical Pharmacology. 2013 Mar 1
• 6 citations
  A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors.
  E. Gabriela Chiorean, Srikar R. Malireddy, Anne Younger, David R. Jones, M. J. Waddell, Melissa I. Sloop, Menggang Yu, Stephen D. Hall, Bryan P. Schneider, Christopher...> ;Cancer Chemotherapy and Pharmacology. 2010 Aug 1
• 1 citations
  Altered First-Pass Effects in a Liver Transplant Recipient Explained Intraindividual Variation in Calcineurin Inhibitor Concentrations: A Case Report
  Srikar R. Malireddy, Amar G. Pinto, Naga Chalasani, J.C. Gorski, Stephen D. Hall> ;Transplantation Proceedings. 2008 Jun 1
• 100 citations
  Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors
  Paul J. Gaglio, Srikar Malireddy, Brian S. Levitt, Dianne Lapointe-Rudow, Jay H. Lefkowitch, Milan Kinkhabwala, Mark Russo, Jean C. Emond, Robert S. Brown> ;Liver Transplantation. 2003 Oct 1
• Join now to see all